Ipsen, a global specialty care-driven biopharmaceutical company, has appointed Laura Réveillon, PhD as EVP, Strategy & Transformation, effective May 14, 2025. She will serve on the Executive Leadership Team and report directly to Ipsen’s Chief Executive Officer (CEO), David Loew.

“We are very pleased to welcome Laura to Ipsen as our EVP for Strategy & Transformation. I have observed Laura’s involvement in major transformation projects across leading life science companies in different fronts – from post-merger integrations, commercial model designs and corporate transformations. She brings a rare combination of strategic vision, analytical rigor and ability to execute across different areas within the healthcare space,” said David Loew.

Experience

Réveillon joins Ipsen from the Boston Consulting Group (BCG) where she was Partner, consulting across portfolio strategy, M&A, Go-to-Market, and operating model transformation projects. Over her 12-year tenure at BCG, Réveillon became a trusted partner for many pharmaceutical companies, having consulted with organizations ranging from small biotech firms to global pharma and MedTech companies. She has been exposed to a diversity of market dynamics, strategic contexts and corporate cultures, proving a strong ability to navigate complex, high-stakes transformations across geographies and business models over her 20-year career in the broader healthcare industry.

“I am very excited to join Ipsen at this moment of the Group’s transformation journey. Having had the opportunity to collaborate with the company in the past years, I am truly excited to jointly define and drive the next chapter of Ipsen’s strategy,” said Réveillon.

Réveillon will succeed Catherine Abi Habib, EVP Strategy & Transformation for the last 3 years, who has been appointed Ipsen’s General Manager for Belgium and Luxembourg.